Fig 1.
Overall survival (OS) of patients with Philadelphia chromosome-positive (Ph+) advanced myeloid leukemias treated with venetoclax and BCR-ABL tyrosine kinase inhibitor-based regimens.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.